ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

KURA Kura Oncology Inc

20,80
-0,28 (-1,33%)
25 Jun 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Kura Oncology Inc KURA NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
-0,28 -1,33% 20,80 19:04:31
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
21,04 20,46 21,14 20,49 21,08
mais cotações »

Notícias Recentes

Data Hora Fonte Título
24/06/202408:30GLOBEKura Oncology Reports Preclinical Data Supporting Potential..
07/06/202408:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
29/05/202408:30GLOBEKura Oncology to Participate in Jefferies Global Healthcare..
14/05/202408:30GLOBEKura Oncology Completes Enrollment in Registration-Directed..
08/05/202408:30GLOBEKura Oncology to Participate in Bank of America Securities..
03/05/202408:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
02/05/202417:05GLOBEKura Oncology Reports First Quarter 2024 Financial Results
25/04/202408:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22/04/202408:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10/04/202408:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05/04/202408:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06/03/202409:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
01/03/202419:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
27/02/202418:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26/02/202409:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22/02/202409:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20/02/202409:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
02/02/202409:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
30/01/202409:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
24/01/202409:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
08/12/202309:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..
28/11/202309:30GLOBEKura Oncology to Participate in the JMP Securities..
02/11/202317:01GLOBEKura Oncology Reports Third Quarter 2023 Financial Results
02/11/202308:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
30/10/202308:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
26/10/202317:05GLOBEKura Oncology to Report Third Quarter 2023 Financial Results
19/10/202308:30GLOBEKura Oncology Announces First Patient Dosed in FIT-001 Trial..
17/10/202317:05GLOBEKura Oncology Announces Positive Results from..
04/10/202308:30GLOBEKura Oncology Announces Three Presentations at..
28/09/202308:30GLOBEKura Oncology Reports Preclinical Data Showing Ability of..
19/09/202308:30GLOBEKura Oncology to Participate in Cantor Global Healthcare..
14/08/202308:30GLOBEKura Oncology Appoints Brian Powl as Chief Commercial..
03/08/202317:05GLOBEKura Oncology Reports Second Quarter 2023 Financial Results
27/07/202308:30GLOBEKura Oncology to Report Second Quarter 2023 Financial..